Introduction
Human esophageal cancer (EC) is one of the most common cancers worldwide and occurs at very high frequencies in certain areas of China, Iran, South Africa, Uruguay, France and Italy. EC ranks sixth in terms of cancer mortality in the world (1).
50 % of EC cases in the world occurred in China and China has the highest mortality rate for EC in five continents. In China, there are many high EC incidence and mortality rate areas. Areas with high mortality rate of EC are located in southern parts of the Taihang Mountains on the borders of Henen, Shansi and Hopei provinces, Lin-xian county in Henen province has the highest age-adjusted mortality rates for EC, which were 151/100 000 for male and 115/100 000 female(2).
Molecular biological studies showed that genetic abnormalities in several oncogenes and tumor suppressor genes frequently occurred in EC and esophageal cancer cell lines (3-5), but the mechanism underlying esophageal cancer tumorigenesis remains poorly understood ( 6 -14) . Most recent studies on this cancer have been focused on cloning and identifying novel esophageal cancer related genes, which might play important roles in the initiation and progression of EC (15, 16). The esophageal cancer related gene 1(ECRG1, GenBank accession no. AF071882.1) was cloned by using mRNA differential display technique to compare gene expression between normal esophageal epithelium and esophageal cancer cells in patients from families with high incidence of (17). Bioinformatics analysis revealed that ECRG1 is a member of the membrane-anchored serine protease family (18), which contains three conserved tandem serine protease domains (His, Asp and Ser) that play a key role in proteolytic activity.
Previous analysis using reverse transcriptase-PCR and Northern blot showed that the ECRG1 gene is expressed in normal esophagus, liver, colon and lung, but its expression is down-regulated in tumor samples, especially in esophageal squamous cell carcinoma(ESCC) and its adjacent normal esophageal squamous epithelium (19). The expression of protein encoded by ECRG1 in E.coli was verified by Western blot assay, the polyclonal antibody was generated by immunizing BALB/c mice with recombinant ECRG-1 protein (20). Furthermore, it has been shown that ECRG1 protein is able to up-regulate P15INK4b expression and induce G1/S cell cycle arrest by association with Myc-interacting Zn finger protein-1 (Miz-1) in esophageal cell line EC9706 (21).
We screened DNA samples from 80 individuals for mutations and SNPs in the coding region of ECRG1. Three SNPs were identified and located in exons 3, 8 and 9, respectively. The SNP in exon 8 (869G A) located in the Asp conserved region of ECRG1 serine protease catalytic domain results in 290Arg-Gln amino acid change (22) . We performed an analysis of 290Arg/Gln polymorphism on 998 EC patients and 1252 controls in a hospital-based, case-control study. We observed a statistically significant increase in risk of EC associated with the ECRG1 290Arg/Gln and 290Gln/Gln genotypes compared to the 290Arg/Arg (22).
In this study, we demonstrated that ECRG-1 gene is involved in cell cycle control and can inhibit the esophageal cancer cell growth in vitro and esophageal tumor formation in vivo.
Materials and Methods
Cell culture: NEC cell line was derived from NMB Z A-treated human fetal esophageal epithelia. Cells were maintained in DMEM with10% newborn calf serum and incubated at 37°C and 5% CO 2 . Human liver cancer BEL-7402 cells were grown in M199 with 10% Newborn calf serum at 37°C and 5% CO 2 . Hek293 cells were grown in DMEM with 10% Newborn calf serum at 37°C and 5% CO 2. Subcellular localization of ECRG1 protein: Human ECRG1 cDNA was subcloned into EcoRI/BamHI site of pEGFP-N1 or pEGFP-C1 (Clontech) to make a C terminus or N terminus fusion to the enhanced GFP. The pEGFP-N1-ECRG1 and pEGFP-C1 ECRG1 were confirmed to be in frame by DNA sequencing. BEL-7402 and Hek293 cells were seeded in 35mm dish and allowed to grow to approximately 80% confluency.
pEGFP-N1-ECRG1 (2ug), pEGFP -C1 ECRG1 (2ug) and EGFP-N1 (2ug) were transfected into the cells. 48 hours after transfection, cells were observed using a fluorescent microscope (Excitation wavelength, 488nm; Emission wavelength, 507nm). than that of NEC cells transfected with empty vector and wild type NEC cells (Fig. 2) .
Inhibition of the tumor growth in nude mice.
NEC cells were transfected with pCDNA3-ECRG-1 or empty vector, stable cell lines were established. NEC cells were injected into nude mice. The tumorigenicity of NEC cells transfected with ECRG1 gene was decreased (Fig.3.A，B) , and the weight and volume of tumors were drastically reduced compared to that of tumors formed by wild type NEC cells and NEC cells with empty vector (Fig.3. C) .
Our findings indicate that ECRG1 gene significantly inhibits the growth of NEC cells both in vitro and in vivo. 
Over-expression of ECRG1 in NEC cells induced G/M cell cycle arrest
In vitro cultured NEC cells transfected with ECRG1 gene were analyzed by flow cytometry. As shown in c, 41.6% of the NEC cells transfected with ECRG1 gene were found in the G2/M stage, only 9.5% of NEC cells(A) and 5.6% of NEC cells(B) with empty vector were at G2/M phase (Fig. 4.) . The flow cytometry analysis showed that over-expression of ECRG-1 in NEC cells is able to induce G2/M cell cycle arrest. 
Discussion

